Loading
Led AZA-001, which showed azacitidine extends survival in high-risk MDS and made hypomethylating agents standard.
Pierre Fenaux (Hôpital Saint-Louis, Paris) was principal investigator of AZA-001, the trial that showed azacitidine improves overall survival compared with conventional care in higher-risk myelodysplastic syndromes, the first drug to do so and the foundation of hypomethylating therapy in MDS and AML. He co-led the European APL trials with Laurent Degos that established all-trans retinoic acid and leads the Groupe Francophone des Myélodysplasies.
| Title | Journal | Year |
|---|---|---|
| Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study (AZA-001) | Lancet Oncology | 2009 |
| Myelodysplastic syndromes | Lancet | 2014 |
| IMerge: imetelstat, a telomerase inhibitor, for transfusion-dependent lower-risk MDS after erythropoietin has failed | The Lancet | 2024 |
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
Shares Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag mds.
Shares Cancer Institute AP-HP Nord, Université Paris Cité, Acute myeloid leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag mds.
Shares Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
Shares Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.
Shares MEDALIST, IMerge: imetelstat, a telomerase inhibitor, for transfusion-dependent lower-risk MDS after erythropoietin has failed, Myelodysplastic syndromes / neoplasms (MDS).